163 related articles for article (PubMed ID: 26389831)
21. [Difference between FOXP3 gene expressions in donor grafts with or without acute graft-versus-host disease].
Wang ZD; Feng SZ; Zhou SY; Wang M; Zhou Z; Zhai WJ; Han MZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1215-20. PubMed ID: 17204197
[TBL] [Abstract][Full Text] [Related]
22. The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation.
Delia M; Carluccio P; Mestice A; Chiusolo P; Metafuni E; Bellesi S; Arpinati M; Milone GA; Martino M; Mazza P; Ingrosso C; Vacca A; Saporiti G; Zallio F; Attolico I; Pastore D; Specchia G; Albano F; Musto P
Transplant Cell Ther; 2021 Nov; 27(11):918.e1-918.e9. PubMed ID: 34403789
[TBL] [Abstract][Full Text] [Related]
23. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
24. Absolute of CD4(+)CD25(+)FOXP3(+) regulatory T-cell count rather than its ratio in peripheral blood is related to long-term survival of renal allografts.
Liu L; Deng S; Teng L; Fu Q; Wang C; He X
Transplant Proc; 2012 Jan; 44(1):284-6. PubMed ID: 22310634
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation.
Schaap N; Schattenberg A; Mensink E; Preijers F; Hillegers M; Knops R; Pennings A; Boezeman J; Geurts van Kessel A; de Pauw B; de Witte T
Leukemia; 2002 Jan; 16(1):13-21. PubMed ID: 11840258
[TBL] [Abstract][Full Text] [Related]
26. Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.
Peterlin P; Delaunay J; Guillaume T; Gastinne T; Mahé B; Dubruille V; Blin N; Le Bourgeois A; Brissot E; Lodé L; Le Gouill S; Moreau P; Mohty M; Chevallier P
Biol Blood Marrow Transplant; 2015 Jan; 21(1):180-4. PubMed ID: 25175796
[TBL] [Abstract][Full Text] [Related]
27. CD4
Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
[TBL] [Abstract][Full Text] [Related]
28. CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation.
Locke FL; Pidala J; Storer B; Martin PJ; Pulsipher MA; Chauncey TR; Jacobsen N; Kröger N; Walker I; Light S; Shaw BE; Beato F; Laport GG; Nademanee A; Keating A; Socie G; Anasetti C
Biol Blood Marrow Transplant; 2017 Mar; 23(3):405-411. PubMed ID: 28007665
[TBL] [Abstract][Full Text] [Related]
29. Effect of Total Nucleated and CD34(+) Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation.
Remberger M; Törlén J; Ringdén O; Engström M; Watz E; Uhlin M; Mattsson J
Biol Blood Marrow Transplant; 2015 May; 21(5):889-93. PubMed ID: 25662230
[TBL] [Abstract][Full Text] [Related]
30. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
31. Frequency of CD4(+)FOXP3(+) regulatory T-cells at early stages after HLA-mismatched allogeneic hematopoietic SCT predicts the incidence of acute GVHD.
Fujioka T; Tamaki H; Ikegame K; Yoshihara S; Taniguchi K; Kaida K; Kato R; Inoue T; Nakata J; Ishii S; Soma T; Okada M; Ogawa H
Bone Marrow Transplant; 2013 Jun; 48(6):859-64. PubMed ID: 23165499
[TBL] [Abstract][Full Text] [Related]
32. FOXP3 expression in peripheral blood rapidly recovers and lacks correlation with the occurrence of graft-versus-host disease after allogeneic stem cell transplantation.
Arimoto K; Kadowaki N; Ishikawa T; Ichinohe T; Uchiyama T
Int J Hematol; 2007 Feb; 85(2):154-62. PubMed ID: 17321995
[TBL] [Abstract][Full Text] [Related]
33. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
van Besien K; Hari P; Zhang MJ; Liu HT; Stock W; Godley L; Odenike O; Larson R; Bishop M; Wickrema A; Gergis U; Mayer S; Shore T; Tsai S; Rhodes J; Cushing MM; Korman S; Artz A
Haematologica; 2016 May; 101(5):634-43. PubMed ID: 26869630
[TBL] [Abstract][Full Text] [Related]
34. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy.
Bensinger WI; Buckner CD; Shannon-Dorcy K; Rowley S; Appelbaum FR; Benyunes M; Clift R; Martin P; Demirer T; Storb R; Lee M; Schiller G
Blood; 1996 Dec; 88(11):4132-8. PubMed ID: 8943847
[TBL] [Abstract][Full Text] [Related]
35. Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT.
Ringdén O; Labopin M; Schmid C; Sadeghi B; Polge E; Tischer J; Ganser A; Michallet M; Kanz L; Schwerdtfeger R; Nagler A; Mohty M;
Br J Haematol; 2017 Feb; 176(3):431-439. PubMed ID: 27879990
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation.
Bensinger WI; Clift R; Martin P; Appelbaum FR; Demirer T; Gooley T; Lilleby K; Rowley S; Sanders J; Storb R; Buckner CD
Blood; 1996 Oct; 88(7):2794-800. PubMed ID: 8839878
[TBL] [Abstract][Full Text] [Related]
37. Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial.
Gooptu M; Kim HT; Chen YB; Rybka W; Artz A; Boyer M; Johnston L; McGuirk J; Shea TC; Jagasia M; Shaughnessy PJ; Reynolds CG; Fields M; Alyea EP; Ho VT; Glavin F; Dipersio JF; Westervelt P; Ritz J; Soiffer RJ
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2216-2223. PubMed ID: 30006305
[TBL] [Abstract][Full Text] [Related]
38. High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.
Reshef R; Huffman AP; Gao A; Luskin MR; Frey NV; Gill SI; Hexner EO; Kambayashi T; Loren AW; Luger SM; Mangan JK; Nasta SD; Richman LP; Sell M; Stadtmauer EA; Vonderheide RH; Mick R; Porter DL
J Clin Oncol; 2015 Jul; 33(21):2392-8. PubMed ID: 26056179
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic bone marrow grafts with high levels of CD4(+) CD25(+) FoxP3(+) T cells can lead to engraftment failure.
Fricke S; Rothe K; Hilger N; Ackermann M; Oelkrug C; Fricke C; Schönfelder U; Niederwieser D; Emmrich F; Sack U
Cytometry A; 2012 Jun; 81(6):476-88. PubMed ID: 22522779
[TBL] [Abstract][Full Text] [Related]
40. Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.
Brierley CK; Jones FM; Hanlon K; Peniket AJ; Hatton C; Collins GP; Schuh A; Medd P; Clark A; Ward J; Chaganti S; Malladi R; Parker A; Craddock C; Danby R; Rocha V
Br J Haematol; 2019 Feb; 184(4):547-557. PubMed ID: 30467838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
